Lung cancer is the leading cause of cancer death in the United States in both men and women. Efforts to treat the advanced disease process have marginally enhanced survival over the last forty years. A reduction in mortality rates are likely to arise from strategies which prevent the disease, enable its recognition early, or enable its treatment successfully. Therefore, novel rational treatment strategies, including gene therapy approaches, are being actively investigated. Although gene therapy is an arena with great potential, to date, its efficacy has been limited. We believe that this lack of efficacy exists primarily because of limitations in therapeutic gene delivery. Our objective is to understand and overcome limitations in gene transfer as they pertain to a model of advanced (malignant pleural effusions) non-small cell lung cancer (NSCLC). Towards this aim, this project is a direct extension of investigations performed by the PI to study the mechanisms whereby adenoviral vectors transport genes into lung cancer cells. Preliminary studies suggest that NSCLC is heterogeneously transduced by the adenoviral (Ad) vector, partly because the cancer cells differ in their ability to bind and internalize the virus. In addition, with respect to in vivo transduction, there are inhibitory soluble factors within the tumor milieu that impede gene transfer by Ad-vectors. The current study aims to characterize the physical properties and mechanisms underlying the inhibition, and to possibly identify the factors which impair Ad-gene transfer in malignant pleural effusions. In addition, the proposal seeks to extend on the principles responsible for mediating efficient gene transfer into lung cancer cells, specifically, how important entry is to Ad-transduction. We believe that the identification of the relevant hurdles to gene therapy will better enable us to develop strategies to overcome those limitations, or to exclude the current generation of Ad-vectors as viable candidates for comprehensive gene therapy of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA078654-03
Application #
6376891
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Gail, Dorothy
Project Start
1999-07-01
Project End
2004-06-30
Budget Start
2001-07-01
Budget End
2004-06-30
Support Year
3
Fiscal Year
2001
Total Cost
$128,439
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Qin, Min; Escuadro, Brian; Sharma, Sherven et al. (2005) Gene transfer mediated by native versus fibroblast growth factor-retargeted adenoviral vectors into lung cancer cells. Am J Respir Cell Mol Biol 32:211-7
Sharma, Sherven; Zhu, Li; Yang, Seok Chul et al. (2005) Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol 175:813-9
Qin, Min; Escuadro, Brian; Dohadwala, Mariam et al. (2004) A novel role for the coxsackie adenovirus receptor in mediating tumor formation by lung cancer cells. Cancer Res 64:6377-80
Yang, Seok-Chul; Hillinger, Sven; Riedl, Karen et al. (2004) Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 10:2891-901
Sharma, Sherven; Stolina, Marina; Yang, Seok-Chul et al. (2003) Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 9:961-8
Qin, Min; Chen, Shuang; Yu, Tina et al. (2003) Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into non-small cell lung cancer xenografts. Clin Cancer Res 9:4992-9
Batra, Raj K; Lin, Ying; Sharma, Sherven et al. (2003) Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I kappa B kinase-dependent mechanism. Cancer Res 63:642-6
Riedl, Karen; Baratelli, Felicita; Batra, Raj K et al. (2003) Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer 2:35
Sharma, Sherven; Yang, Seok-Chul; Hillinger, Sven et al. (2003) SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2:22
Hillinger, Sven; Yang, Seok-Chul; Zhu, Li et al. (2003) EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J Immunol 171:6457-65

Showing the most recent 10 out of 22 publications